Ignite Creation Date:
2025-12-26 @ 10:43 PM
Ignite Modification Date:
2026-03-21 @ 11:10 PM
Study NCT ID:
NCT01560312
Status:
TERMINATED
Last Update Posted:
2019-02-01
First Post:
2012-03-19
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Renal Denervation in Refractory Hypertension
Sponsor:
Charles University, Czech Republic
Organization:
Study Overview
Official Title:
Renal Denervation - Hope for Patients With Refractory Hypertension?
Status:
TERMINATED
Status Verified Date:
2019-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Based on analysis of our data after the Symplicity-3 trial announcement, decision for study termination was done.
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PRAGUE-15
Brief Summary:
Open, multicenter, randomized study is enrolling patients in 3 sites in Czech Republic. Patients with refractory hypertension will be randomized in 1:1 manner either to renal denervation plus optimal medical antihypertensive treatment without spironolactone or to antihypertensive treatment alone including spironolactone if not contraindicated. The primary end-point is change in Systolic and Diastolic Blood Pressure (BP) between baseline and 1 year after randomization evaluated by 24-hours BP monitoring. Expected enrollment is 120 patients. Patients follow-up is planned for 3 years.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: